LINXING HUANG

Ms. LINXING HUANG


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2023 in Acta Neurologica Belgica
Verified
Journal Article
Open access
PDF file
LHLINXING HUANG
LINXING HUANG
LYLizhen Yi
Lizhen Yi
HHHuiyuan Huang
Huiyuan Huang
SZSheng Zhan
Sheng Zhan
RCRuixue Chen
Ruixue Chen
ZYZenghui Yue
Zenghui Yue
Stroke is the third leading cause of death and disability worldwide. Post-stroke spasticity (PSS) is the most common complication of stroke but represents only one of the many manifestations of upper motor neuron syndrome. As an upper motor neuron, the corticospinal tract (CST) is the only direct descending motor pathway that innervates the spinal motor neurons and is closely related to the recovery of limb function in patients with PSS. Therefore, promoting axonal remodeling in the CST may help identify new therapeutic strategies for PSS. In this review, we outline the pathological mechanisms of PSS, specifically their relationship with CST, and therapeutic strategies for axonal regeneration of the CST after stroke. We found it to be closely associated with astroglial scarring produced by astrocyte activation and its secretion of neurotrophic factors, mainly after the onset of cerebral ischemia. We hope that this review offers insight into the relationship between CST and PSS and provides a basis for further studies.

23 February 2024 in Medicine
Verified
Journal Article
Open access
RCRuixue Chen
Ruixue Chen
HHHuiyuan Huang
Huiyuan Huang
SZSheng Zhan
Sheng Zhan
LYLizhen Yi
Lizhen Yi
LHLINXING HUANG
LINXING HUANG
ZYZenghui Yue
Zenghui Yue
Background: This study aimed to evaluate the efficacy and safety of electroacupuncture (EA) in the treatment of benign prostatic hyperplasia. Methods: Seven databases were searched from the inception of each database to March 31, 2023, including PubMed, Web of Science, Cochrane, Embase, China National Knowledge Infrastructure, Wanfang, and China Biology Medicine. The modified Jadad scale was used to assess literature quality, and literature inclusion and exclusion were conducted in strict accordance with the criteria of a score of ≥4. The risk of bias was evaluated using the Cochrane risk of bias tool. The pooled effect size of the binary data was measured by odds ratio (OR) and 95% confidence interval (CI), and the pooled effect size of the continuous data was presented as weighted mean difference (WMD) and 95% CI. If I² was larger than 50%, a random effects model was adopted, and otherwise, a fixed effects model was used. Additionally, publication bias assessment and sensitivity analysis were conducted. Results: A total of 325 records were retrieved, and finally 9 randomized controlled trial studies were included, involving 1045 patients. Meta-analysis revealed that the EA group had better improvement than the control group in terms of clinical effective rate (odds ratio = 3.92, 95% CI = 2.38 to 6.47, I² = 0%, P < .001), International Prostate Symptom Score (WMD = −4.99, 95% CI = −6.15 to −3.84, I² = 76.9%, P < .001), maximum urinary flow rate (WMD = −4.99, 95% CI = −6.15 to −3.84, I² = 87.4%, P < .001), and post-void residual volume (WMD = −17.12, 95% CI = −29.49 to −4.75, I² = 89.1%, P < .01). There was no statistical significance in prostate volume and adverse events between the EA group and the control group (P > .05). Conclusion: EA is effective in the treatment of benign prostatic hyperplasia with acceptable overall safety.